NRx Pharmaceuticals, Inc. — Form 10-K Summary
Business context and reporting period
NRx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for central nervous system disorders through NeuroRx, Inc. The filing covers the fiscal year ended December 31, 2022 and was filed March 31, 2023. The company has no product revenue and remains dependent on external financing.
The principal program is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone, intended to treat severe bipolar depression with suicidality. NRX-100 is intravenous racemic ketamine, intended for acute stabilization before NRX-101 in the original sequential-therapy approach. The company also retains development opportunities in PTSD and chronic pain.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $17.0 million | $20.3 million |
| General and administrative expense | $27.3 million | $74.9 million |
| Total operating expenses | $44.3 million | $115.8 million |
| Net loss | $39.8 million | $93.1 million |
| Net loss per share | $0.60 | $1.98 |
| Net cash used in operating activities | $39.8 million | $37.7 million |
| Cash and cash equivalents at year-end | $20.1 million | $27.6 million |
| Total liabilities | $18.4 million | $11.9 million |
| Stockholders’ equity | $7.4 million | $20.8 million |
Operating expenses and net loss declined substantially in 2022, primarily because 2021 included significant non-cash stock compensation, consulting expense and GEM settlement expense. The 2022 loss included a $4.6 million gain from the reduction of the Earnout Cash liability, a $0.5 million increase in the fair value of the convertible note, and a $0.3 million gain from warrant remeasurement.
Liquidity, debt and capital resources
- Financing activities provided $32.2 million in 2022, including $22.7 million net proceeds from a February 2022 private placement and approximately $10.0 million net proceeds from the Streeterville convertible note.
- The November 2022 note had approximately $11.0 million face value, a 9% interest rate, an 18-month term and a December 31, 2022 carrying value of $10.5 million. The lender may redeem up to $1.0 million per month beginning six months after issuance, with payment potentially required in cash or shares at a discounted conversion price.
- At December 31, 2022, $7.7 million of the note was classified as current and $2.8 million as long-term. Events of default may accelerate repayment and increase the interest rate to as much as 18%, subject to applicable law.
- Management and the auditors stated that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. The financial statements contain no going-concern adjustments.
- On March 9, 2023, the company completed a registered direct offering of 3,866,666 shares and warrants for gross proceeds of approximately $2.9 million. The company stated that additional financing would be needed during 2023.
Material changes versus the prior comparable period
- Research and development expense decreased by $3.2 million, primarily because of lower ZYESAMI-related clinical and development costs.
- General and administrative expense decreased by $47.6 million, largely because 2021 included $53.3 million of consulting-related costs, including equity compensation, and higher stock-based compensation.
- Settlement expense declined from $21.4 million in 2021 to zero in 2022.
- Net loss improved by $53.3 million, from $93.1 million to $39.8 million, but cash used in operations increased by approximately $2.1 million.
- Cash declined by $7.6 million during 2022, compared with a $25.7 million increase in 2021.
- Total liabilities increased by $6.5 million, primarily due to the Streeterville convertible note.
- The $4.6 million Earnout Cash liability was eliminated because the applicable milestones were not achieved by December 31, 2022.
- The company transferred its ZYESAMI aviptadil assets to Relief Therapeutics in December 2022, ending its active development efforts for the product. NRx retained potential milestone payments of up to $13.0 million and royalties capped at $30.0 million, but realization is contingent on Relief’s future development and commercialization.
- The company reported that a previously identified material weakness in internal control over financial reporting was remediated as of December 31, 2022.
Guidance, outlook, risks and unusual items
- NRX-101 received FDA Fast Track and Breakthrough Therapy designations, a Biomarker Letter of Support and a Special Protocol Agreement. These designations do not assure approval.
- FDA feedback in January 2023 suggested broadening the NRX-101 program to include patients with recent acute suicidality regardless of stabilization method and generating a larger safety database for chronic or intermittent use. The company is evaluating the timing and cost implications.
- The company is considering consolidating the ASIB and SSIB development programs. It expects top-line data from the consolidated trial in the first quarter of 2024, but patient recruitment and regulatory execution remain uncertain.
- The ongoing Phase IIb/III study’s independent DSMB found no safety signal and no futility signal in its interim reviews, but these findings do not establish efficacy or predict regulatory approval.
- The company expects to initiate a Phase II PTSD study in the second half of 2023 and may initiate a chronic-pain pilot study, subject to available funding.
- NRX-101 manufacturing was transferred from China to a U.S. contract manufacturer, and commercial-scale material was produced. The company has not yet demonstrated manufacturing at sustained commercial volumes.
- NRx is defending a GEM arbitration demand involving an alleged HK$15.0 million, approximately $1.9 million, commitment fee. The company disputes that the fee is owed.
- The company has no product liability insurance currently, although it carries clinical-trial liability insurance and expects to seek product liability coverage closer to commercialization.
- Major risks include clinical-trial failure or delay, FDA or DEA requirements, manufacturing and supply-chain execution, dependence on third parties and licensed intellectual property, competition, dilution from future financings, potential Nasdaq delisting, and continued negative cash flow.
Most important facts for investors to verify
- Whether the company can raise sufficient capital to fund operations, clinical trials and debt redemptions beyond 2023.
- The terms, repayment mechanics and potential dilution associated with the Streeterville convertible note.
- Enrollment status, statistical powering, interim monitoring and final results of the NRX-101 Phase IIb/III program.
- Whether FDA guidance changes the indication, safety-database requirements, trial design or expected NDA timing.
- Whether manufacturing can be scaled consistently to commercial standards and volumes.
- The status and potential exposure of the GEM arbitration and any other employment or commercial claims.
- Whether Relief Therapeutics develops ZYESAMI sufficiently to generate the disclosed milestones or royalties.
- Future equity issuance, warrant exercises and their effect on ownership dilution and Nasdaq listing compliance.